This study will aim to assess how effective the next generation of BTX-A-HAC (BTX-A-HAC NG) with an injectable liquid formulation is for improving the appearance of lines (wrinkles) between the eyebrows (glabellar area)

Woman and Man

| Country :
| organs :
| Specialty :

Extract

The primary study objective is to demonstrate the efficacy of a single treatment of an injectable liquid form of Clostridium botulinum toxin type A haemagglutinin complex (BTX A HAC; hereafter referred to as BTX A HAC Next Generation (BTX A HAC NG)), used for the improvement in the appearance of moderate to severe glabellar lines at maximum frown. The primary objective will be accomplished by demonstrating the superiority of BTX A HAC NG over placebo assessed by the Investigator’s live assessment (ILA) of the appearance of glabellar lines at maximum frown at Day 29.

Inclusion criteria

moderate-to-severe glabellar lines

Kusajili – Clinical trials directory

This study will aim to assess how effective the next generation of BTX-A-HAC (BTX-A-HAC NG) with an injectable liquid formulation is for improving the appearance of lines (wrinkles) between the eyeb...